Anika Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Anika Therapeutics
ANIK Stock  USD 15.86  0.25  1.55%   
Anika Therapeutics financial statements provide useful quarterly and yearly information to potential Anika Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Anika Therapeutics financial statements helps investors assess Anika Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Anika Therapeutics' valuation are summarized below:
Gross Profit
76.6 M
Profit Margin
(0.47)
Market Capitalization
235.9 M
Enterprise Value Revenue
1.6796
Revenue
119.9 M
There are currently one hundred twenty fundamental signals for Anika Therapeutics that can be evaluated and compared over time across rivals. We recommend to validate Anika Therapeutics' prevailing fundamental drivers against the all of the trends between 2010 and 2025. Market Cap is expected to rise to about 608.3 M this year. Enterprise Value is expected to rise to about 537.5 M this year

Anika Therapeutics Total Revenue

66.01 Million

Check Anika Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Anika Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 17.2 M, Interest Expense of 1.3 M or Selling General Administrative of 119 M, as well as many indicators such as Price To Sales Ratio of 1.92, Dividend Yield of 0.0 or PTB Ratio of 1.71. Anika financial statements analysis is a perfect complement when working with Anika Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Anika Therapeutics Correlation against competitors.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.

Anika Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets150.3 M202.7 M230.6 M
Slightly volatile
Short and Long Term Debt Total15.6 M24 M19.4 M
Slightly volatile
Other Current Liabilities18.6 M17.7 M11.4 M
Slightly volatile
Total Current Liabilities12.3 M23.3 M17.1 M
Slightly volatile
Total Stockholder Equity122.4 M154 M194.2 M
Slightly volatile
Property Plant And Equipment Net67.9 M64.7 M52.6 M
Slightly volatile
Accounts Payable3.8 M5.6 M5.1 M
Slightly volatile
Cash55.1 M55.6 M81.5 M
Slightly volatile
Non Current Assets Total56.8 M89.1 M89.3 M
Slightly volatile
Cash And Short Term Investments62.2 M55.6 M93.1 M
Pretty Stable
Net Receivables13.8 M23.6 M22.1 M
Slightly volatile
Common Stock Shares Outstanding12.8 M14.7 M13.8 M
Slightly volatile
Liabilities And Stockholders Equity150.3 M202.7 M230.6 M
Slightly volatile
Non Current Liabilities Total15.7 M25.4 M19.3 M
Slightly volatile
Inventory14 M23.8 M21.5 M
Slightly volatile
Other Current Assets11.2 M10.6 M5.9 M
Slightly volatile
Other Stockholder Equity56.1 M89 M64.8 M
Slightly volatile
Total Liabilities27.9 M48.8 M36.4 M
Slightly volatile
Property Plant And Equipment Gross148.1 M141 M62.2 M
Slightly volatile
Total Current Assets93.6 M113.7 M141.3 M
Slightly volatile
Short Term Debt1.6 M2.5 M1.2 M
Slightly volatile
Non Currrent Assets Other14.3 M13.6 M7.1 M
Slightly volatile
Common Stock Total Equity139.2 K167.9 K142.5 K
Slightly volatile
Common Stock140.8 K144 K141.2 K
Slightly volatile
Property Plant Equipment32.3 M55.5 M42.2 M
Slightly volatile
Current Deferred Revenue1.4 M1.4 M5 M
Pretty Stable
Other Liabilities8.1 M6.2 M7.6 M
Slightly volatile
Good Will8 M7.1 M7.6 M
Pretty Stable
Intangible Assets2.4 M2.5 M24.1 M
Pretty Stable
Net Tangible Assets227.7 M267.3 M198.1 M
Slightly volatile
Long Term Debt Total7.7 M8.6 M9.4 M
Slightly volatile
Capital Surpluse52.5 M73 M67.6 M
Pretty Stable
Non Current Liabilities Other441.4 K464.6 K2.3 M
Very volatile
Net Invested Capital214 M191 M257.6 M
Slightly volatile
Net Working Capital132.6 M119 M172.8 M
Slightly volatile
Capital Stock158.6 K169.1 K145.5 K
Slightly volatile
Capital Lease Obligations26.9 M33.4 M24.1 M
Slightly volatile

Anika Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization17.2 M16.3 M8.5 M
Slightly volatile
Selling General Administrative119 M113.3 M44.7 M
Slightly volatile
Total Revenue66 M119.9 M102.3 M
Slightly volatile
Gross Profit42.6 M76 M67.7 M
Slightly volatile
Other Operating Expenses131.3 M125 M94.9 M
Slightly volatile
Cost Of Revenue23.4 M43.9 M34.6 M
Slightly volatile
Total Operating Expenses85.2 M81.1 M58.9 M
Slightly volatile
Research Development26.8 M25.5 M16.6 M
Slightly volatile
Interest Income2.3 M2.2 M1 M
Slightly volatile
Reconciled Depreciation11.4 M16.5 M8.2 M
Slightly volatile
Extraordinary Items1.8 M2.1 M2.3 M
Slightly volatile

Anika Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation4.2 M8.1 M6.9 M
Slightly volatile
Capital Expenditures4.2 M7.7 M4.8 M
Slightly volatile
End Period Cash Flow55.1 M57.2 M81.5 M
Slightly volatile
Begin Period Cash Flow54.9 M72.9 M79.7 M
Slightly volatile
Stock Based Compensation12.5 M13.1 M85.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.922.02084.326
Slightly volatile
PTB Ratio1.711.57352.1972
Pretty Stable
Days Sales Outstanding54.4671.820777.4343
Slightly volatile
Book Value Per Share6.6910.460513.484
Slightly volatile
Average Payables2.4 M1.8 M2.3 M
Slightly volatile
Stock Based Compensation To Revenue0.10.10953.0033
Slightly volatile
Capex To Depreciation0.90.95231.1595
Slightly volatile
PB Ratio1.711.57352.1972
Pretty Stable
EV To Sales2.551.75713.6224
Pretty Stable
Inventory Turnover1.481.84421.7491
Slightly volatile
Days Of Inventory On Hand283198242
Very volatile
Payables Turnover6.227.81727.7054
Very volatile
Sales General And Administrative To Revenue0.30.370.3004
Very volatile
Average Inventory11.1 M10.5 M10.6 M
Slightly volatile
Research And Ddevelopement To Revenue0.20.2130.1562
Slightly volatile
Capex To Revenue0.110.06450.0865
Slightly volatile
Cash Per Share3.493.77896.4856
Pretty Stable
Days Payables Outstanding79.8646.692164.5331
Slightly volatile
Intangibles To Total Assets0.04510.04740.1247
Pretty Stable
Current Ratio6.94.876510.0539
Pretty Stable
Tangible Book Value Per Share5.669.807411.2527
Slightly volatile
Receivables Turnover7.255.08214.9535
Pretty Stable
Shareholders Equity Per Share6.6910.460513.484
Slightly volatile
Debt To Equity0.130.15590.0968
Pretty Stable
Capex Per Share0.550.52540.3716
Slightly volatile
Graham Net Net2.852.4785.8259
Very volatile
Average Receivables17 M16.1 M16.9 M
Slightly volatile
Revenue Per Share8.558.14537.392
Slightly volatile
Interest Debt Per Share1.881.791.3763
Slightly volatile
Debt To Assets0.09650.11840.077
Slightly volatile
Graham Number10.7110.2117.4005
Pretty Stable
Operating Cycle358270321
Very volatile
Price Book Value Ratio1.711.57352.1972
Pretty Stable
Days Of Payables Outstanding79.8646.692164.5331
Slightly volatile
Company Equity Multiplier1.431.31661.2281
Very volatile
Long Term Debt To Capitalization0.140.160.1296
Slightly volatile
Total Debt To Capitalization0.120.13490.0879
Pretty Stable
Debt Equity Ratio0.130.15590.0968
Pretty Stable
Quick Ratio5.993.85498.7256
Pretty Stable
Net Income Per E B T21.4220.39983.3102
Slightly volatile
Cash Ratio4.132.38696.0473
Pretty Stable
Cash Conversion Cycle278223256
Pretty Stable
Days Of Inventory Outstanding283198242
Very volatile
Days Of Sales Outstanding54.4671.820777.4343
Slightly volatile
Price To Book Ratio1.711.57352.1972
Pretty Stable
Fixed Asset Turnover1.761.85392.0289
Pretty Stable
Debt Ratio0.09650.11840.077
Slightly volatile
Price Sales Ratio1.922.02084.326
Slightly volatile
Asset Turnover0.360.59140.437
Pretty Stable
Gross Profit Margin0.460.63380.6231
Very volatile
Price Fair Value1.711.57352.1972
Pretty Stable

Anika Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap608.3 M579.3 M524.1 M
Slightly volatile
Enterprise Value537.5 M511.9 M459.2 M
Slightly volatile

Anika Fundamental Market Drivers

Forward Price Earnings51.2821
Cash And Short Term Investments55.6 M

Anika Upcoming Events

4th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Anika Therapeutics Financial Statements

Anika Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Anika Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue1.4 M1.4 M
Total Revenue119.9 M66 M
Cost Of Revenue43.9 M23.4 M
Stock Based Compensation To Revenue 0.11  0.10 
Sales General And Administrative To Revenue 0.37  0.30 
Research And Ddevelopement To Revenue 0.21  0.20 
Capex To Revenue 0.06  0.11 
Revenue Per Share 8.15  8.55 
Ebit Per Revenue(0.04)(0.04)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Anika Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Anika Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Anika Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Anika Therapeutics Stock:
How To Invest In Anika
Details
Is Anika Stock a good investment?
Details
What is Anika Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Anika Therapeutics Correlation against competitors.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.51)
Earnings Share
(0.60)
Revenue Per Share
8.145
Quarterly Revenue Growth
(0.29)
Return On Assets
(0.01)
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY